ALT (Altimmune, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by ALT officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-13 | Jerome Benedict Durso | President and CEO | Buy | — | — |
| 2026-08-03 | GREGORY L WEAVER | Chief Financial Officer | A | — | — |
| 2026-08-03 | M Scot Roberts | Chief Scientific Officer | A | — | — |
| 2026-05-01 | Philip Hodges | Director | A | — | — |
| 2026-05-01 | MITCHEL SAYARE | Director | A | — | — |
| 2026-05-01 | Diane Jorkasky | Director | A | — | — |
| 2026-05-01 | Klaus Schafer | Director | A | — | — |
| 2026-05-01 | Catherine A. Sohn | Director | A | — | — |
| 2026-05-01 | Teri L Lawver | Director | A | — | — |
| 2026-05-01 | Wayne Pisano | Director | A | — | — |
| 2026-05-01 | JOHN GILL | Director | A | — | — |
| 2026-04-06 | JOHN GILL | Director | Buy | — | — |
| 2026-04-01 | GREGORY L WEAVER | Chief Financial Officer | Buy | — | — |
| 2026-04-01 | Jerome Benedict Durso | President and CEO | Buy | — | — |
| 2026-03-09 | GREGORY L WEAVER | Chief Financial Officer | Buy | — | — |
| 2026-03-09 | Jerome Benedict Durso | President and CEO | Buy | — | — |
| 2026-02-27 | M Scot Roberts | Chief Scientific Officer | A | — | — |
| 2026-02-27 | GREGORY L WEAVER | Chief Financial Officer | A | — | — |
| 2026-02-03 | M Scot Roberts | Chief Scientific Officer | MIXED | — | — |
| 2026-02-02 | Raymond M Jordt | Chief Business Officer | A | — | — |
| 2026-02-02 | Vipin K Garg | Director | MIXED | — | — |
| 2026-01-29 | Raymond M Jordt | Chief Business Officer | MIXED | — | — |
| 2026-01-29 | M Scot Roberts | Chief Scientific Officer | MIXED | — | — |
| 2026-01-29 | Vipin K Garg | Director | MIXED | — | — |
| 2026-01-27 | M Scot Roberts | Chief Scientific Officer | MIXED | — | — |
| 2026-01-27 | Raymond M Jordt | Chief Business Officer | MIXED | — | — |
| 2026-01-27 | Vipin K Garg | Director | MIXED | — | — |
| 2026-01-09 | Wayne Pisano | Director | Buy | — | — |
| 2026-01-05 | Catherine A. Sohn | Director | Buy | — | — |
| 2026-01-05 | Raymond M Jordt | Chief Business Officer | MIXED | — | — |
| 2025-12-29 | Diane Jorkasky | Director | Buy | — | — |
| 2025-12-23 | JOHN GILL | Director | Buy | — | — |
| 2025-12-22 | Jerome Benedict Durso | Director | Buy | — | — |
| 2025-12-01 | Jerome Benedict Durso | CEO-elect | A | — | — |
| 2025-11-12 | GREGORY L WEAVER | Chief Financial Officer | MIXED | — | — |
| 2025-10-03 | GREGORY L WEAVER | Chief Financial Officer | A | — | — |
| 2025-10-03 | Christophe Arbet-Engels | Chief Medical Officer | A | — | — |
| 2025-09-29 | Diane Jorkasky | Director | A | — | — |
| 2025-09-29 | Klaus Schafer | Director | A | — | — |
| 2025-09-29 | Teri L Lawver | Director | A | — | — |
| 2025-09-29 | Wayne Pisano | Director | A | — | — |
| 2025-09-29 | Philip Hodges | Director | A | — | — |
| 2025-09-29 | Catherine A. Sohn | Director | A | — | — |
| 2025-09-29 | Jerome Benedict Durso | Director | A | — | — |
| 2025-09-29 | JOHN GILL | Director | G | — | — |
| 2025-09-29 | MITCHEL SAYARE | Director | A | — | — |
| 2025-09-17 | Linda M Richardson | Chief Commercial Officer | A | — | — |
| 2025-08-04 | Raymond M Jordt | Chief Business Officer | A | — | — |
| 2025-08-04 | M Scot Roberts | Chief Scientific Officer | A | — | — |
| 2025-08-04 | Matthew Scott Harris | Chief Medical Officer | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 8,345,145 | — |
| — | 10%+ Owner | 4,500,000 | — |
| — | 10%+ Owner | 3,500,000 | — |
| — | 10%+ Owner | 1,687,250 | — |
| — | President and CEO | 429,225 | — |
| — | 10%+ Owner | 186,579 | — |
| — | Chief Scientific Officer | 113,714 | — |
| — | Chief Medical Officer | 83,874 | — |
| — | Director | 83,859 | — |
| — | Chief Business Officer | 70,107 | — |
| — | President and CEO | 62,500 | — |
| — | Chief Financial Officer | 40,391 | — |
| — | Chief Financial Officer | 39,831 | — |
| — | Director | 27,451 | — |
| — | Director | 26,579 | — |
| — | Director | 21,700 | — |
| — | Director | 18,771 | — |
| — | Chief Financial Officer | 17,721 | — |
| — | Director | 13,498 | — |
| — | President and CEO | 12,195 | — |
| — | Acting Chief Financial Officer | 11,372 | — |
| — | Director | 9,179 | — |
| — | 10%+ Owner | 5,048 | — |
| — | Director | 1,500 | — |
| — | President & CEO | 595 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ALT quote page; the site-wide leaderboard is on the insider transactions hub.